Project Grant R21EB038528
- The National Institute of Biomedical Imaging and Bioengineering awarded The University of Texas Southwestern Medical Center $536,853 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award funds development and validation of a comprehensive 7 Tesla MRI framework for simultaneous high-resolution mapping of brain iron and myelin in mesoscale brain structures. The project integrates three complementary...
- The National Institute of Biomedical Imaging and Bioengineering awarded The University of Texas Southwestern Medical Center $138,813 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to support Dr. Mai Thuan Huynh's transition to independent investigator status in metabolism and molecular imaging research. The award funds design, synthesis, and validation of advanced carbon tracers to image...
- The National Institute of Biomedical Imaging and Bioengineering awarded The University of Texas Southwestern Medical Center $207,500 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286, Assistance Listing project grant R21EB038569) to develop hyperpolarized 15N-labeled nicotinamide riboside as a magnetic resonance spectroscopy probe for monitoring NAD+ and NADH levels in vivo. The funded research addresses...
- The National Institute of Biomedical Imaging and Bioengineering awarded Vanderbilt University Medical Center $393,750 on August 17, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a double saturation technique for chemical exchange saturation transfer (CEST) imaging that enhances glycogen quantification at clinical 3T MRI field strength. The funded work develops DSP-CEST, a novel quantification method that...
- The National Institute of Biomedical Imaging and Bioengineering, a component of the Department of Health and Human Services National Institutes of Health, awarded $184,063 to the University of Texas at San Antonio on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award funds development of forced-dimerization activated photoacoustic aptamer switch sensors (FDA-PASS), optical probes designed to enable...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of Texas at Dallas $186,674 on August 7, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop fullwave physics-informed recurrent neural networks for ultrasound simulation, quantitative imaging, and adaptive focusing. The project addresses barriers to clinical adoption of quantitative ultrasound by developing a single...
- The National Institute of Biomedical Imaging and Bioengineering awarded the Regents of the University of Michigan $149,264 on March 26, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop magnetic resonance fingerprinting (MRF) technology for myocardial tissue characterization in patients with cardiac implantable electronic devices. The project addresses the clinical underutilization of cardiac MRI in CIED...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $1,677,898 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop fat and iron-corrected quantitative MRI T1 mapping as a non-invasive biomarker for evaluating chronic liver disease, particularly metabolic-associated steatohepatitis (MASH). The project addresses the clinical need for non-invasive assessment of liver pathology...
- The National Institute of Biomedical Imaging and Bioengineering awarded New York University School of Medicine $114,562 on June 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop and validate a novel diffusion MRI framework for prostate cancer imaging. The recipient will develop a fast, high-resolution, distortion-free diffusion-weighted imaging protocol for the prostate that overcomes limitations in current...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $117,426 to the University of California, San Diego on June 18, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a noninvasive MRI method for assessing bone quality in type 2 diabetes patients. The project develops an ultrashort echo time quantitative magnetization transfer (UTE-QMT) MRI technique to measure collagen crosslinking in cortical bone, a bone quality...
The National Institute of Biomedical Imaging and Bioengineering awarded The University of Texas Southwestern Medical Center $236,834 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a novel magnetic resonance spectroscopy imaging sequence for non-invasive assessment of skeletal muscle metabolites in type 2 diabetes. The project develops a metabolite cycled semi-laser localized 4D echo planar total correlated spectroscopic imaging (EP-TOCSI) sequence to examine skeletal muscle metabolites and lipids in clinically feasible scan time. The sequence enables simultaneous water and metabolite acquisition without extending scan time, improving quantification of intramyocellular lipids, taurine, carnosine, acetylcarnitine, and other metabolites linked to glucose metabolism and insulin resistance. The work uses 30 individuals with type 2 diabetes and 30 healthy controls to develop and validate the sequence on a whole-body 3T MRI/MRS scanner, with specific aims including sequence development and phantom validation on healthy adults, quantification of upfield lipids and metabolites, and comparison of metabolite profiles between study groups. The project runs through August 31, 2028, with performance in Dallas, Texas. The Discovery and Applied Research program supports hypothesis-, design-, technology-, or device-driven research related to discovery, design, development, validation, and application of technologies for biomedical imaging and bioengineering.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $236.8k | 8/25/26 |